Posts by Sandra Ansanay-Alex
EPFL Latsis Symposium
The EPFL Latsis Symposium 2026: “Decoding the Cell: Modeling, Predicting, and Engineering Cellular States” is taking place on 29-30 October 2026 at the Olympic Museum in Lausanne. This two-day symposium brings together world-leading scientists at the intersection of computational biology, single-cell genomics, bioengineering, and cellular engineering – including speakers from Stanford, Cambridge, Harvard, the Wellcome Sanger Institute, and ETH Zurich, among…
Read MoreABILITY Neurotech Receives IMDD Approval to Start Clinical Trial for Chronic Implantation of BCI in ALS Patients
ABILITY Neurotech, a Geneva-based clinical-stage brain-computer interface company, announced it has received Investigational Medical Device Dossier (IMDD) approval from the Medical Research Ethics Committee (MREC) NedMec in the Netherlands to launch its first chronic implantation study of a fully implantable wireless optical-link ECoG BCI in amyotrophic lateral sclerosis (ALS) patients. This milestone represents the company’s…
Read MoreEli Lilly Makes Three Strategic Acquisitions to Bolster Its Vaccine Portfolio
Eli Lilly, the American pharmaceutical giant with a Swiss presence through its branch in Vernier, in the canton of Geneva, has announced the simultaneous acquisition of three companies — Curevo (US), LimmaTech Biologics (Switzerland), and Vaccine Company (US) — in a bold move to strengthen its position in differentiated vaccine technologies and address major unmet…
Read MoreEurope BioBank Week Congress
Europe BioBank Week Congress is taking place from 18 to 21 May 2027 at EPFL, at the Swiss Tech Convention Center. Here is a first glimpse of the provisional programme*, being prepared for the international biobanking community in Lausanne: DAY 1. On-site visits will be organized to explore different biobanks within the Swiss network, as…
Read MoreMindMaze Announces a CHF 8.0 Million Equity Financing with Neuro.io
MindMaze Therapeutics Holding SA, a Lausanne-based global leader in scalable precision neurotherapeutics, announces it has entered into a definitive agreement for a CHF 8.0 million equity financing with Neuro.io Group SA, through which Neuro.io will acquire a strategic equity position in the company. The proceeds will support the company’s commercial priorities, including scaling its U.S.…
Read MoreA New Humanoid Robotics School in Renens
Asinov School — School of Embodied Intelligence — will open its doors in September 2026 in Renens, within UniverCité/Station R innovation ecosystem in the canton of Vaud. Students will be trained in building humanoid robots for healthcare, industry, logistics, and services. The initiative is a joint venture between the Dalle Molle Foundation, the Inartis Foundation…
Read MoreInside TRB Chemedica: a visit to one of Valais’ quiet pharmaceutical powerhouses
Tucked away in Vouvry, in the Swiss canton of Valais, TRB Chemedica is the kind of company that rarely makes headlines yet quietly supplies patients around the world. A delegation from Swiss Valley recently had the opportunity to tour the site, discover its manufacturing processes, and walk the prefilled-syringe filling lines first-hand. The company specialises…
Read MoreHAYA Therapeutics doses first cohort in Phase 1 trial of a precision therapy for cardiac fibrosis
Swiss-American biotech HAYA Therapeutics has dosed the first cohort in the Phase 1 clinical trial of HTX-001, its lead investigational therapy and a first-in-class candidate aimed at the underlying fibrosis that drives heart disease. HTX-001 is an antisense oligonucleotide designed to downregulate WISPER, a heart stress-specific long non-coding RNA (lncRNA) that is overexpressed in patients…
Read MoreSwiss Biotool Startup Bionomous Launches Sortivo
Swiss biotool startup Bionomous has launched Sortivo™, an automated benchtop platform for the gentle screening, sorting, and plating of complex biological entities — a step the company says will help labs adopt New Approach Methodologies (NAMs), the non-animal alternatives increasingly favoured by regulators. Sortivo handles delicate biological entities ranging from roughly 300 μm to 2…
Read MoreNeurosoft Bioelectronics Closes $7.5M Oversubscribed Seed Round
Geneva-based neurotechlogy company Neurosoft Bioelectronics announces that it has raised a $7.5 million oversubscribed seed financing round. Headquartered in Campus Biotech with a US presence in New York, the company is developing a scalable and soft brain-computer interfaces (BCIs). The funds will be used to advance clinical trials across both the United States and Europe.…
Read More